There are three broad treatment options for patients
with acute myelogenous leukemia (AML): palliative care only, standard approaches
involving chemotherapy with or without hematopoietic stem cell transplantation,
and investigational approaches studied in the context of a formal clinical
trial, also involving chemotherapy and transplantation. Given the natural
history of the illness (as established by Freireich et al in the 1950s and
1960s), it would be difficult to recommend a purely palliative strategy
except perhaps in the elderly and/or infirm, as discussed below.
The choice between standard and experimental therapy largely depends on the
prognosis following use of the former, and disease prognosis is so variable that
it suggests AML is, in fact, several different diseases. This article considers
the various prognostic subsets and therapies for AML.
In the United States today, most AML patients receive standard therapy under
the care of their private physician as described in this article. The two phases
of standard treatment of AML are induction of a complete remission (CR) and
postremission therapy. Terms such as consolidation, maintenance, or
intensification often are used in connection with postremission therapy.
Consolidation refers to treatment that is only slightly less intense than
induction therapy, maintenance therapy is relatively less intense than
consolidation, and intensification therapy rivals or surpasses induction in dose
The goal of therapy is achievement of a CR (< 5% blasts in the marrow, a
neutrophil count exceeding 1,000-1,500/µL, and a platelet count greater than
100,000/µL); such a remission generally has been assumed necessary, although
not adequate, for prolonged survival. The differences in survival rates between
patients who achieve complete remissions and those who do not have been shown to
be almost entirely dependent upon the time they spend in CR. This observation
suggests that the achievement of CR per se, rather than a difference in inherent
prognosis between responders and nonresponders, is paramount.
The disease recurs in the majority of patients who achieve CRs, making it
likely that not all of these remissions are a result of the same degree of
antileukemic activity. A future clinical challenge will be to distinguish
between significant and cosmetic CR, since the latter predicts especially high
relapse rates unless therapy is changed. Such distinctions eventually will be
made by using polymerase chain reaction (PCR) technology to detect persistent
evidence of a presenting cytogenetic abnormality,[3-5] immunophenotyping to
identify persistent aberrant patterns of cell surface antigens, or simple
clinical observation based on data suggesting that the longer the time required
to achieve CR, the shorter the subsequent CR.[7,8]
At any rate, once 2 years have elapsed from the onset of CR, the risk of
relapse declines precipitously, with this risk continuing to decrease
thereafter. Once 3 years have elapsed from the CR date, the likelihood of
relapse becomes < 10%, and it is reasonable to consider patients potentially
cured at that time.
Standard induction therapy generally consists of a combination of an
anthracycline and cytarabine (ara-C), with the anthracycline often administered
for 3 days and ara-C for 7 days ("3 + 7" regimens). Numerous
randomized studies have compared the efficacy of the anthracyclines daunorubicin
(Cerubidine), mitoxantrone (Novantrone), and idarubicin (Idamycin) when all are
given with 7 days of ara-C.[10-12] In general, most studies, including a large
meta-analysis, found idarubicin to be superior, although differences are
less apparent in older patients.
Several comments about standard anthracycline regimens should be considered:
- Results may vary if different doses (eg, 60 mg/m², rather than 45 or 50
mg/m², of daunorubicin daily) of the several anthracyclines are used.
- Survival gains among the various anthracyclines are relatively modest (ie,
median survivals generally differ by only several months).
- Results from the same treatment regimen (eg, daunorubicin plus ara-C) in
several trials at times exceed the differences among other regimens in the same
These observations make it difficult to attach great significance to the
choice of anthracycline regimens for untreated AML.
Randomized trials have found essentially the same results regardless of the
dose of ara-C (100 or 200 mg/m² daily by continuous infusion for
7 days) or the addition of either thioguanine or etoposide to
the 3 + 7 regimen (with the latter finding obtained in the largest related trial
conducted to date).
Once patients achieve CR, they typically receive several cycles of
consolidation or maintenance therapy employing the initial drugs; treatment is
then stopped and the patient observed. Current data indicate that some
postremission therapy is beneficial, but how much therapy remains unclear, since
durations of therapy are 2 years vs 3 months and 16 vs 7 months in supporting
Again, several comments may be in order. First, benefits generally relate to
disease-free survival rather than to overall survival, and have not been
universally noted.[19,20] Second, the reasons for these discrepancies are
unclear, but they might reflect the myelosuppression produced by the
maintenance, the intensity of the therapy given prior to maintenance, or, given
the variability of AML, the particular mix of patients treated. In any event, we
will assume that prolonging maintenance with these agents for more than 6 months
has relatively little effect on survival, while recognizing that the issue has
not been, and is unlikely to be, unequivocally resolved because of other
Other standard approaches to postremission therapy are allogeneic or
autologous hematopoietic stem cell transplantations, using cyclophosphamide (Cytoxan,
Neosar) plus total-body irradiation or busulfan (Myleran)/cyclophosphamide and high-dose
On average, standard therapy produces median survival durations of 6 to
12 months and CR rates of approximately 60% to 65%; the median duration of
remission is approximately 1 year, with 15% to 20% of the patients potentially
cured. However, these results are inherently misleading, because only a minority
of patients can be considered to conform to an average. For most patients,
outcome is either better or worse than this average, depending on a well-defined
set of prognostic factors.
1. Freireich EJ, Gehan EA, Sulman D, et al: The effect of chemotherapy on
acute leukemia in the human. J Chron Dis 14:593-601, 1961.
2. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer
Institute-sponsored workshop on definitions of diagnosis and response in acute
myeloid leukemia. J Clin Oncol 8:813-819, 1990.
3. Hebert J, Cayuela JM, Daniel MT, et al: Detection of minimal residual
disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by
nested polymerase chain reaction with allele specific amplification. Blood
4. Downing JR, Head DR, Curcio-Brent MG, et al: An AML1/ETO fusion transcript
is consistently detected by RNA-based polymerase chain reaction in acute
myelogenous leukemia containing the (8;21) (q22;q22) translocation. Blood
5. Diverio D, Pandolfi PP, Biondi A, et al: Absence of reverse
transcription-polymerase chain reaction detectable residual disease in patients
with acute promyelocytic leukemia in long-term remission. Blood 82:3556-3559,
6. Vidriales MB, López-Berges MC, Díaz-Mediavilla J, et al: Early
immunophenotypical evaluation of minimal residual disease (MRD) in AML
identifies different risk-groups of patients, and can contribute to
post-induction treatment stratification (abstract 2336). Blood 96(11):544a,
7. Keating MJ, Smith TL, Gehan EA, et al. Factors related to length of
complete remission in adult acute leukemia. Cancer 45:2017-2029, 1980.
8. Estey E, Shen Y, Thall PF: Effect of time to complete remission on
subsequent survival and disease-free survival time in AML, RAEB-t and RAEB.
Blood 95(1):72-77, 2000.
9. DeLima M, Strom SS, Keating M, et al: Implications of potential cure in
acute myelogenous leukemia: Development of subsequent cancer and return to work.
Blood 90:4719-4724, 1997.
10. Berman E, Heller G, Santorsa J, et al: Results of a randomized trial
comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine
arabinoside in adult patients with newly-diagnosed acute myelogenous leukemia.
Blood 77:1666-1674, 1991.
11. Wiernik PH, Banks PLC, Case DC, et al: Cytarabine plus idarubicin or
daunorubicin as induction and consolidation therapy for previously untreated
adult patients with acute myeloid leukemia. Blood 79:313-319, 1992
12. Vogler WR, Velez-Garcia E, Weiner RS, et al: A phase III trial comparing
idarubicin and daunorubicin in combination with cytarabine in acute myelogenous
leukemia: A Southeastern Cancer Study Group study. J Clin Oncol 10:1103-1111,
13. Wheatley K, on the behalf of the AML Collaborative Group: Meta-analysis
of randomized trials of idarubicin (IDAR) or mitoxantrone (MITO) vs daunorubicin
(DNR) as induction therapy for acute myeloid leukemia (AML) (abstract). Blood
86(suppl 1):434a, 1995.
14. Dilman RO, Davis RB, Green MR, et al: A comparative study of two
different doses of cytarabine for acute myeloid leukemia: A phase III trial of
Cancer and Leukemia Group B. Blood 78:2520-2526, 1991.
15. Preisler H, Davis RB, Kirshner J, et al, and the Cancer and Leukemia
Group B: Comparison of three remission induction regimens and two post induction
strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and
Leukemia Group B study. Blood 69:1441-1449, 1987.
16. Hann IM, Stevens RF, Goldstone AH, et al: Randomized comparison of DAT
versus ADE as induction chemotherapy in children and younger adults with acute
myeloid leukemia: Results of the Medical Research Council’s 10th AML trial (MRC
AML10). Blood 89:2311-2318, 1997.
17. Büchner T, Grbanitz D, Hiddemann W, et al: Intensified induction and
consolidation with or without maintenance chemotherapy for acute myeloid
leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J
Clin Oncol 3:1583-1589, 1985.
18. Ohno R, Kobayashi T, Tanimoto M, et al: Randomized study of
individualized induction therapy between 4 and 12 courses in adult acute myeloid
leukemia (AML-87 Study of the Japan Adult Leukemia Study Group). Cancer
19. Sauter C, Fopp M, Imbach P, et al: Acute myelogenous leukemia:
Maintenance chemotherapy after early consolidation treatment does not prolong
survival. Lancet 1:379-382, 1984.
20. Champlin R, Gale RP, Elashoff R, et al: Prolonged survival in acute
myelogenous leukemia without maintenance chemotherapy. Lancet 1:894-896, 1984.
21. Estey E, Keating MJ, McCredie KB, et al: Causes of initial remission
induction failure in acute myelogenous leukemia. Blood 60:309-315, 1982.
22. Anderlini P, Luna M, Kantarjian HM, et al: Causes of initial remission
induction failure in patients with acute myeloid leukemia and myelodysplastic
syndromes. Leukemia 10:600-608, 1996.
23. Thall P, Estey E: Graphical methods for evaluating covariate effects in
the Cox model, in Crowley J (ed): Handbook of Statistics in Clinical Oncology.
New York, Marcel Dekker, 2001.
24. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization
Classification of neoplastic diseases of the hematopoietic and lymphoid tissue:
Report of the Clinical Advisory Committee MeetingAirlie House, Virginia,
November 1997. J Clin Oncol 3835-3849, 1999.
25. Grimwade D, Waler H, Oliver F, et al: The importance of diagnostic
cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC
AML 10 trial. Blood 92(7):2322-2333, 1998.
26. Leith CP, Kopecky KJ, Godwin J, et al: Acute myeloid leukemia in the
elderly: Assessment of multidrug resistance (MDR1) and cytogenetics
distinguishes biologic subgroups with remarkably distinct responses to standard
chemotherapy: A Southwest Oncology Group study. Blood 89:3323-3329, 1997.
27. Leith CP, Kopecky KJ, Chen I, et al: Frequency and clinical significance
of the expression of the multidrug resistance proteins MDR1/P-glycoprotein,
MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study. Blood
28. DeLima M, Ghaddar H, Pierce S, et al: Treatment of newly-diagnosed acute
myelogenous leukemia in patients age 80 years and above. Br J Haematol 93:89-95,
29. Weick JK, Kopecky KJ, Appelbaum FR, et al: A randomized investigation of
high-dose vs standard-dose cytosine arabinoside with daunorubicin in patients
with previously untreated acute myeloid leukemia: A Southwest Oncology Group
Study. Blood 88:2841-2851, 1996.
30. Bishop JF: Approaches to induction therapy in AML. Leuk Lymphoma
31. Cassileth PA, Lynch E, Hines JD, et al: Varying intensity of
postremission therapy in acute myeloid leukemia. Blood 79:1924-1930, 1992.
32. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission
chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903,
33. Bloomfield CD, Lawrence D, Byrd JC, et al: Frequency of prolonged
remission duration after high-dose cytosine arabinoside intesification in AML
varies by cytogenetic sybtype. Cancer Res 58:4173-4179, 1998.
34. Ghaddar HM, Plunkett W, Kantarjian HM, et al: Long-term results following
treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion
high-dose cytosine arabinoside. Leukemia 8:1269-1274, 1994.
35. Visani G, Baccarani M, Bernasconi P, et al: The prognostic value of
cytogenetics is reinforced by the kind of induction therapy in influencing the
outcome of acute myeloid leukemiaAnalysis of 848 patients (abstract 3570).
Blood 96(11):826a, 2000.
36. Gandhi V, Estey E, Keating MJ, et al: Fludarabine potentiates metabolism
of arabinosyl cytosine in patients with acute myelogenous leukemia during
therapy. J Clin Oncol 11:116-124, 1993.
37. Estey E, Thall P, Wang X: Routine use of fludarabine-or
topotecan-containing chemotherapy is not indicated in AML, RAEB-t or RAEB
(abstract 2170). Blood 96(11):504a, 2000.
38. Zittoun RA, Mandelli F, Willemze R, et al: Autologous or allgeneic bone
marrow transplantation compared with intensive chemotherapy in acute myelogenous
leukemia. N Engl J Med 332(4):217-223, 1995.
39. Cassileth PA, Harrington DP, Appelbaum FR, et al: Chemotherapy compared
with autologous or allogeneic bone marrow transplantation in the management of
acute myeloid leukemia in first remission. N Engl J Med 339(23):1649-1656, 1998.
40. Burnett AK, Goldstone AH, Stevens R, et al: Randomised comparison of
addition of autologous bone-marrow transplantation to intensive chemotherapy for
acute myeloid leukemia in first remission: Results of MRC AML 10 trial. Lancet
41. Woods WG, Neudorf S, Gold S, et al: Aggressive postremission chemotherapy
is better than autologous bone marrow transplantation and allogeneic BMT is
superior to both in children with acute myeloid leukemia (abstract 1091). Proc
Am Soc Clin Oncol 15:368a, 1996.
42. Burnett AK, Goldstone AH, Stevens R, et al: Biological characteristics of
disease determine the outcome of allogeneic or autologous BMT in AML CR1
(abstract). Blood 86(suppl 1):614a, 1995.
43. Burnett AK: Transplantation in first remission of acute myeloid leukemia.
N Engl J Med 339:1698-700, 1998.
44. Stevens RF, Hann IM, Wheatley K, et al: Marked improvements in outcome
with chemotherapy alone in paediatric acute myeloid leukemia: Results of the
United Kingdom Medical Research Council’s 10th AML trial. Br J Haematol
45. Tallman MS, Rowlings PA, Milone G, et al: Effect of postremission
chemotherapy before human leukocyte antigen-identical sibling transplantation
for acute myelogenous leukemia in first complete remission. Blood
46. Slavin S: Treatment of myeloid leukemias with non-myeloablative stem cell
transplantation: Accomplishments and future goals. Hematology 2000, pp 81-89.
American Society of Hematology Education Program Book, 2000.
47. Berman E, Little C, Gee T, et al: Reasons that patients with acute
myelogenous leukemia do not undergo allogeneic bone marrow transplantation. N
Engl J Med 326:156, 1992.
48. Proctor SJ, Taylor PRA, Stark A, et al: Evaluation of the impact of
allogeneic transplant in first remission on an unselected population of patients
with acute myeloid leukemia aged 15-55 years. Leukemia 9:1246-1251, 1995.
49. Sievers EL, Appelbaum FR, Spielberger RT, et al: Selective ablation of
acute myeloid leukemia using antibody-targeted chemotherapy: A phase II study of
an anit-CD33 calicheamicin immunoconjugate. Blood 93(11):3678-3684, 1999.
50. Leopold LH, Berger MS, Cheng S, et al: Comparative efficacy and safety of
gemtuzumab oxogamicin monotherapy and high-dose cytarabine combination therapy
in the treatment of patients with acute myeloid leukemia in first relapse
(abstract 2171). Blood 96(11):504a, 2000.
51. Jurcic JG, McDevitt MR, Sgouros G, et al: Phase I trial of targeted
alpha-particle therapy for myeloid leukemias with bismuth-213-HuM195 (anti-CD33)
(abstract 22). Proc Am Soc Clin Oncol 18:7a, 1999.
52. Matthews DC, Appelbaum FR, Eary JF, et al: Phase I study of
131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for
advanced acute leukemia and myelodyplastic syndrome. Blood 94:1237-1347, 1999.
53. List AF, Kopecky KJ, Willman CL, et al: Benefit of cycloporine (CsA)
Modulation of anthracycline resistance in high-risk AML: A Southwest Oncology
Group study (abstract). Blood 98(12):3212-3220, 2001.
54. Baer MR, George SL, Dodge RK: Phase III study of PSC-833 modulation of
multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML)
patients (PTS) ³ 60 years of age (CALGB 9720) (abstract 1704). Blood 94:383a,
55. Greenberg P, Advani R, Tallman M, et al: Treatment of refractory/relapsed
AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC:
Randomized phase III trial (E2995) (abstract 1703). Blood 94:383a, 1999.
56. Kolitz JE, George SL, Hurd D, et al: Parallel phase I trials of
multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients
(PTS) with acute myeloid leukemia (AML) < 60 years old: preliminary results
of CALGB 9621 (abstract 1705). Blood 94(10):384a, 1999.
57. Konopleva M, Andreeff M: Regulatory pathways in programmed cell death.
Cancer Mol Biol 6:1229-1260, 1999.
58. Waters JS, Webb A, Cunnigham D, et al: Bcl-2 antisense therapy in
patients with non-Hodgkin’s lymphoma. J Clin Oncol 18:1812-1823, 2000.
59. Marcucci G, Bloomfield CD, Balcerzak SP, et al: Phase I trial of
genasenseTM (G3139, Genta, Inc.), a BCL-2 antisense (AS), in refractory (REF) or
relapsed (REL) acute leukemia (AL) (abstract 513). Blood 96(11):119a, 2000.
60. Singal R, Ginder GD: DNA methylation. Blood 93:4059-4070, 1999.
61. Kantarjian HM, O’Brien SM, Estey E, et al: Decitabine studies in
chronic and acute myelogenous leukemia. Leukemia 11(suppl 1):S35-S36, 1997.
62. Redner RL, Wang J, Liu JM: Chromatin remodeling and leukemia: New
therapeutic paradigms. Blood 94:417-428, 1999.
63. Hussong JW, Rodgers GM, Shami PJ: Evidence of increased antiogenesis in
patients with acute myeloid leukemia. Blood 95:309-313, 2000.
64. Padro T, Ruiz S, Bieker R, et al: Increased antiogenesis in the bone
marrow of patients with acute myeloid leukemia. Blood 95:2637-2644, 2000.
65. Aguayo A, Estey E, Kantarjian H, et al: Cellular vasular endothelial
growth factor is a predictor of outcome in patients with acute myeloid leukemia.
Blood 94:3717-3721, 1999.
66. Estey E, Albitar M, Cortes J, et al: Addition of thalidomide (T) to
chemotherapy did not increase remission rate in poor prognosis AML/MDS (abstract
1394). Blood 96(11):323a, 2000.
67. Heinrich M, Zigler A, Griffith D, et al: Selective pharmacological
inhibition of wild type and mutant c-kit receptor tyrosine kinase activity in
hematopoietic cells (abstract 265). Blood 94(11):62a, 1999.
68. Tse K, Allebach J, Bohmer FD, et al: Inhibition of the transforming
activity of FLT3 internal tandem duplications derived from AML patients by a
tyrosine kinase inhibitor of the tyrphostin class (abstract 3130). Blood
69. Kottaridis PD, Gale RE, Frew ME, et al: The presence of a FLT3 mutation
in AML adds important prognostic information to cytogenetic risk group and
response to the first cycle of chemotherapy: Analysis of 854 patients from the
MRC AML 10 and 12 trials (abstract 3568). Blood 96(11):825a, 2000.
70. Beaupre DM, Kurzrock R: RAS and leukemia: From basic mechanisms to
gene-directed therapy. J Clin Oncol 17(3):1071-1079, 1999.
71. Lancet J, Rosenblatt J, Liesveld JL, et al: Farnesyl Transferase
Inhibitor R115777 in relapsed and refractory acute leukemias: Preliminary
results of a phase I trial (abstract 5B) . Proc Am Soc Clin Oncol 19:3a, 2000.
72. Giles FJ, Cortes JE, Baker SD, et al: Troxacitabine, a novel dioxolane
nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol
73. Estey E: Treatment of relapsed and refractory acute myelogenous leukemia.
Leukemia 14(3):476-479, 2000.
74. Keating MJ, Kantarjian H, Smith TL, et al: Response to salvage therapy
and survival after relapse in acute myelogenous leukemia. J Clin Oncol
75. Estey E, Thall PF, Pierce S, et al: Treatment of newly diagnosed acute
promyelocytic leukemia without cytarabine. J Clin Oncol 15:483-490, 1997.
76. Sanz MA, LoCoco F, Martin G, et al: Definition of relapse risk and role
of nonanthracycline drugs for consolidation in patients with acute promyelocytic
leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood
77. Fenaux P, Chastang C, Dombret H, et al: Treatment of newly diagnosed
acute promyelocytic leukemia (APL) by all-trans retinoic acid (ATRA) combined
with chemotherapy: The European experience. Leuk Lymphoma 16(5-6):431-437, 1995.
78. Estey E, Giles F, Kantarjian H, et al: Molecular remissions induced by
liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute
promyelocytic leukemia. Blood 94(7):2230-2235, 1999.
79. Frankel SR, Eardley A, Heller G, et al: All-trans retinoic acid for acute
promyelocytic leukemia. Ann Intern Med 120:278, 1994.
80. Soignet SL, Grankel S, Tallman M, et al: Arsenic trioxide (ATO) in
relapsed acute promyelocytic leukemia (APL): The combine results and follow-up
from the U.S. pilot and multicenter trials (abstract 3575). Blood 96(11):827a,
81. Jurcic JG, DeBlasio T, Dumont L, et al: Molecular remission induction
with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute
promyelocytic leukemia. Clin Cancer Res 6:372-380, 2000.
82. LoCoco F, Diverio D, Avvisati G, et al: Therapy of molecular relapse in
acute promyelocytic leukemia. Blood 94(7):2225-2229, 1999.
83. LoCoco F, Diverio D, Pandolfi PP, et al: Molecular evaluation of residual
disease as a predictor of relapse in acute promyelocytic leukemia. Lancet
84. Avvisati G, LoCoco F, Diverio D, et al: AIDA (all-trans retinoic acid +
idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano
Malattie Ematologiche Maligne dell’ Adulto (GIMEMA) pilot study. Blood
85. Diverio D, Rossi V, Avvisati G, et al: Early detection of relapse by
prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha
fusion gene in patients with acute promyelocytic leukemia enrolled in the
GIMEMA-AIEOP multicenter "AIDA" trial. Blood 92:784-789, 1998.